



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

8<sup>th</sup> March, 2021

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001.

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclosed herewith the Press Release for your information.

Thanking you,

Yours faithfully,  
For NATCO Pharma Limited

*M. Adinarayana*

M. Adinarayana  
Company Secretary &  
Vice President (Legal and Corp. Affairs)

Encl: a.a.



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 16 /2020-2021

Press Release

## NATCO receives final approval for Everolimus tablets (generic for Afinitor®) for the US market

*Hyderabad, India, March 8<sup>th</sup>, 2021*

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for Afinitor®) from the U.S. Food and Drug Administration (USFDA).

NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and license agreement entered into with the owner of the Afinitor® brand. The launch date of 10mg strength of the product will be announced at a later date.

The above strengths of Everolimus are indicated in the treatment of breast cancer and a few other types of cancers. As per industry sales data, Afinitor® and its therapeutic equivalents had generated annual sales of \$712 million in USA during the twelve months ending December 2020.

*\*All brand names and trademarks are the property of their respective owners.*

---

Forwarded for favour of publication

For NATCO Pharma Limited

A handwritten signature in black ink that reads "M Adinarayana".

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp. Affairs)